Merck Receives FDA Fast Track Designation for Evofosfamide for Treatment of Patients Living With Advanced Pancreatic Cancer
Darmstadt, Germany (ots/PRNewswire) - - NOT INTENDED FOR US AND UK BASED MEDIA - - Evofosfamide is an investigational compound currently in Phase III trials - Advanced pancreatic cancer is second indication to receive FDA fast track designation for evofosfamide Merck, a leading company for innovative and top-quality ...